<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00045318</url>
  </required_header>
  <id_info>
    <org_study_id>DAIICHI-8951A-PRT026</org_study_id>
    <secondary_id>UCLA-0201008</secondary_id>
    <secondary_id>CDR0000256866</secondary_id>
    <secondary_id>NCI-G02-2103</secondary_id>
    <nct_id>NCT00045318</nct_id>
  </id_info>
  <brief_title>Exatecan Mesylate in Treating Patients With Advanced Solid Tumors and Kidney Dysfunction</brief_title>
  <official_title>A Phase I Study of DX-8951f (Exatecan Mesylate for Injection) in Patients With Renal Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of exatecan mesylate in treating patients&#xD;
      who have advanced solid tumors and kidney dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of exatecan mesylate in patients with advanced&#xD;
           solid tumors and varying degrees of renal dysfunction.&#xD;
&#xD;
        -  Determine the dose-limiting and non-dose-limiting toxic effects of this drug in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the effects of renal dysfunction on the plasma pharmacokinetics and&#xD;
           pharmacodynamics of this drug in these patients.&#xD;
&#xD;
        -  Establish a model for dosing this drug in patients with impaired renal function.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to&#xD;
      severity of renal dysfunction (normal vs mild vs moderate vs severe).&#xD;
&#xD;
      Patients receive exatecan mesylate IV over 30 minutes on days 1-5. Courses repeat every 3&#xD;
      weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients in each renal dysfunction stratum receive escalating doses of&#xD;
      exatecan mesylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as&#xD;
      the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
      Patients in the normal renal function stratum do not undergo dose escalation.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 45 patients (6 normal, 9 mild, 12 moderate, and 18 severe renal&#xD;
      dysfunction) will be accrued for this study within 1.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exatecan mesylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced solid tumor refractory to standard&#xD;
             therapy or for which no standard therapy exists&#xD;
&#xD;
          -  Renal function as defined by the following parameters:&#xD;
&#xD;
               -  Normal (creatinine clearance (CrCl) greater than 80 mL/min)&#xD;
&#xD;
               -  Mild dysfunction (CrCl 50-80 mL/min)&#xD;
&#xD;
               -  Moderate dysfunction (CrCl 30-50 mL/min)&#xD;
&#xD;
               -  Severe dysfunction (CrCl less than 30 mL/min)&#xD;
&#xD;
               -  End-stage renal disease (requiring dialysis)&#xD;
&#xD;
          -  No symptomatic or active brain metastases (e.g., edema or progression on CT scan or&#xD;
             MRI)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST or ALT no greater than 2 times upper limit of normal&#xD;
&#xD;
          -  Albumin at least 2.8 g/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No active congestive heart failure&#xD;
&#xD;
          -  No uncontrolled angina&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent serious infection&#xD;
&#xD;
          -  No other life-threatening illness&#xD;
&#xD;
          -  No overt psychosis or mental disability or other incompetency that would preclude&#xD;
             informed consent&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent anticancer biologic therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosourea) and&#xD;
             recovered&#xD;
&#xD;
          -  No prior exatecan mesylate&#xD;
&#xD;
          -  No other concurrent anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent anticancer hormonal therapy&#xD;
&#xD;
          -  Concurrent megestrol for appetite stimulation allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent anticancer radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery and recovered&#xD;
&#xD;
          -  No concurrent anticancer surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 4 weeks since prior investigational drugs including analgesics or antiemetics&#xD;
&#xD;
          -  At least 1 week since prior grapefruit juice&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other investigational drugs during and for 4 weeks after study&#xD;
&#xD;
          -  No concurrent grapefruit juice&#xD;
&#xD;
          -  No other concurrent anticancer cytotoxic therapy&#xD;
&#xD;
          -  Concurrent chronic hemodialysis or ambulatory peritoneal dialysis allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolyn Britten, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy and Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Lutheran Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - San Antonio (Murphy)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2003</verification_date>
  <study_first_submitted>September 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exatecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

